Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262)

Drozitumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal antibody targeted against the death receptor DR5 (TRAILR2, CD262, TNFRSF10B) with potent anti-tumor activity against rhabdomyosarcoma (RMS) xenografts. MW: 150 kD.
Supplier Selleck Chemicals
Product # A2758
Sku # A2758-1mg*25
Pricing 1mg*25, $5070.00
Feedback